Key statistics
As of last trade, Iovance Biotherapeutics Inc (2LB:FRA) traded at 9.10, 192.89% above the 52 week low of 3.11 set on Oct 19, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.10 |
---|---|
High | 9.10 |
Low | 9.10 |
Bid | 8.87 |
Offer | 8.94 |
Previous close | 9.17 |
Average volume | 722.14 |
---|---|
Shares outstanding | 303.51m |
Free float | 275.98m |
P/E (TTM) | -- |
Market cap | 3.08bn USD |
EPS (TTM) | -1.68 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 07:02 BST.
More ▼
Announcements
- Iovance Biotherapeutics to Present at Upcoming Conferences
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
- Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024
- Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
- Iovance Biotherapeutics to Present at Upcoming Conferences and Events
- Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
- Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
- Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
- Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
More ▼